Having achieved positive proof-of-concept, apitegromab has provided evidence of the potential to treat SMA and may represent a unique, SMN-independent approach, specifically targeting both forms of promyostatin; more specifically, a muscle-targeted therapeutic option for patients that still experience motor function deficits despite SMN protein-increasing therapy. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.